Clinical Trials in Tennessee

Showing 7081-7100 of 20,239 trials

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

NCT05271292

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.

Small Cell Lung CancerAdvanced Solid Malignant Tumor

Chipscreen Biosciences, Ltd.36 participantsStarted Aug 2022

Encinitas, California, United States • Fullerton, California, United States • Atlanta, Georgia, United States +8 more locations

COMPLETEDPhase 129 miles

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT01798004

This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread. Giving chemotherapy to the entire body before a stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

GanglioneuroblastomaStage 1 NeuroblastomaStage 2 Neuroblastoma+5 more

Children's Oncology Group150 participantsStarted Apr 2013

Birmingham, Alabama, United States • Downey, California, United States • Duarte, California, United States +120 more locations

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Find Trials by Condition in Tennessee

Belimumab Assessment of Safety in SLE

Oral Nutritional Supplementation in Children at Risk of Undernutrition

Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Design Validation of Toric Contact Lenses in Senofilcon A With a Blue-Blocking Chromophore

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis

C-myc Biomarker Study for Diabetic Foot Ulcers

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Feasibility Study on LITT for Medical Refractory Epilepsy

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa

AI-enabled Endoscopic Prediction of Post-operative Recurrence in Crohn's Disease